Cargando…
Toxin-Based Targeted Therapy for Malignant Brain Tumors
Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287048/ https://www.ncbi.nlm.nih.gov/pubmed/22400035 http://dx.doi.org/10.1155/2012/480429 |
_version_ | 1782224610522038272 |
---|---|
author | Chandramohan, Vidyalakshmi Sampson, John H. Pastan, Ira Bigner, Darell D. |
author_facet | Chandramohan, Vidyalakshmi Sampson, John H. Pastan, Ira Bigner, Darell D. |
author_sort | Chandramohan, Vidyalakshmi |
collection | PubMed |
description | Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages. |
format | Online Article Text |
id | pubmed-3287048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32870482012-03-07 Toxin-Based Targeted Therapy for Malignant Brain Tumors Chandramohan, Vidyalakshmi Sampson, John H. Pastan, Ira Bigner, Darell D. Clin Dev Immunol Review Article Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages. Hindawi Publishing Corporation 2012 2012-02-09 /pmc/articles/PMC3287048/ /pubmed/22400035 http://dx.doi.org/10.1155/2012/480429 Text en Copyright © 2012 Vidyalakshmi Chandramohan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Chandramohan, Vidyalakshmi Sampson, John H. Pastan, Ira Bigner, Darell D. Toxin-Based Targeted Therapy for Malignant Brain Tumors |
title | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
title_full | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
title_fullStr | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
title_full_unstemmed | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
title_short | Toxin-Based Targeted Therapy for Malignant Brain Tumors |
title_sort | toxin-based targeted therapy for malignant brain tumors |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287048/ https://www.ncbi.nlm.nih.gov/pubmed/22400035 http://dx.doi.org/10.1155/2012/480429 |
work_keys_str_mv | AT chandramohanvidyalakshmi toxinbasedtargetedtherapyformalignantbraintumors AT sampsonjohnh toxinbasedtargetedtherapyformalignantbraintumors AT pastanira toxinbasedtargetedtherapyformalignantbraintumors AT bignerdarelld toxinbasedtargetedtherapyformalignantbraintumors |